Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: Involvement of CB1 and NMDA receptors

American Journal of Translational Research

Volumn 9, Issue 2, 2017, Pages 261-274

  Maya López, Marisol ^a,b   Colín González, Ana Laura ^a   Aguilera, Gabriela ^a   de Lima, María Eduarda ^a   Colpo Ceolin, Ana ^a   Rangel López, Edgar ^a   Villeda Hernández, Juana ^a   Rembao Bojórquez, Daniel ^a   Túnez, Isaac ^c   Luna López, Armando ^a   Lazzarini Lechuga, Roberto ^b   González Puertos, Viridiana Yazmín ^b   Posadas Rodríguez, Pedro ^b   Silva Palacios, Alejandro ^b   Königsberg, Mina ^b   Santamaría, Abel ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

^c Universidad de Cordoba   (Spain)

Author keywords

3 Nitropropionic acid; Cannabinoid receptor agonists; Endocannabinoid system; Mitochondrial energy depletion; Neuroprotection; WIN55,212 2

Indexed keywords

3 NITROPROPIONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG; WIN55 212 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOLOGY; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LIPID PEROXIDATION; LIPID PEROXIDATION ASSAY; MALE; MOTOR ACTIVITY; MTT ASSAY; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PROTEIN EXPRESSION; RAT;

EID: 85014339435     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Self DW. Anandamide: a candidate neurotransmitter heads for the big leagues. Nature Neurosci 1999; 2: 303-304.
2. Morales M, Bonci A. Getting to the core of addiction: Hooking CB2 receptor into drug abuse? Nat Med 2012; 18: 504-505.
3. Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2012; 26: 92-103.
4. Rangel-López E, Colín-González AL, Paz-Loyola AL, Pinzón E, Torres I, Serratos IN, Castellanos P, Wajner M, Souza DO, Santamaría A. Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain. Neuroscience 2015; 285: 97-106.
5. Lauckner JE, Hille B, Mackie K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 2005; 102: 19144-19149.
6. Pertwee RG. Pharmacological actions of can-nabinoids. Handb Exp Pharmacol 2005; 168: 1-51.
7. Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson’s disease. Prog Neurobiol 2012; 96: 69-86.
8. Schinder AF, Olson EC, Spitzer NC, Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996; 16: 6125-6133.
9. Hariharan A, Shetty S, Shirole T, Jagtap AG. Potential of protease inhibitor in 3-nitropropionic acid induced Huntington’s disease like symptoms: mitochondrial dysfunction and neurodegeneration. Neurotoxicology 2014; 45: 139-148.
10. Túnez I, Tasset I, Pérez-De La Cruz V, Santamaria A, 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington’s disease: past, present and future. Molecules 2010; 15: 878-916.
11. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. J Neurochem 2005; 95: 1521-1540.
12. Burtscher J, Zangrandi L, Schwarzer C, Gnaiger E. Differences in mitochondrial function in ho-mogenated samples from healthy and epileptic specific brain tissues revealed by high-reso-lution respirometry. Mitochondrion 2015; 25: 104-112.
13. Chaturvedi RK, Beal MF. Mitochondrial disease of the brain. Free Radic Biol Med 2013; 63: 1-29.
14. Lopachin RM, Geohagen BC, Gavin T. Synaptosomal toxicity and nucleophilic targets of 4-hy-droxy-2-nonenal. Toxicol Sci 2009; 107: 171-181.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
16. Balistreri E, Garcia-Gonzalez E, Selvi E, Akhmetshina A, Palumbo K, Lorenzini S, Maggio R, Lucattelli M, Galeazzi M, Distler JW. The cannabinoid WIN55,212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann Rheum Dis 2011; 70: 695-699.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
18. Tatem KS, Quinn JL, Phadke A, Yu Q, Gordish-Dressman H, Nagaraju K. Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J Vis Exp 2014; 91: 51785.
19. Sánchez-Blázquez P, Rodríguez-Muñóz M, Garzón J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 2014; 4: 169.
20. Page KJ, Besret L, Jain M, Monaghan EM, Dunnett SB, Everitt BJ. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. Exp Brain Res 2000; 130: 142-150.
21. Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, Fernández-Ruiz J, Di Marzo V. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease. Neuroreport 2001; 12: 2125-2129.
22. Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease. Synapse 2002; 44: 23-35.
23. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperki-nesia in a rat model of Huntington’s disease. J Neurochem 2003; 84: 1097-1109.
24. Lastres-Becker I, Gómez M, De Miguel R, Ramos JA, Fernández-Ruiz J. Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease. Neurotox Res 2002; 4: 601-608.
25. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004; 15: 2375-2379.
26. de Lago E, Urbani P, Ramos JA, Di Marzo V, Fernández-Ruiz J. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington’s disease. Brain Res 2005; 1050: 210-216.
27. de Lago E, Fernández-Ruiz J, Ortega-Gutiérrez S, Cabranes A, Pryce G, Baker D, López-Rodríguez M, Ramos JA. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington’s disease and multiple sclerosis, but fails to delay/ arrest the progression of different motor-relat-ed disorders. Eur Neuropsychopharmacol 2006; 16: 7-18.
28. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007; 26: 843-851.
29. Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 2011; 42: 524-529.
30. Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropio-nate-lesioned mice. Neurotherapeutics 2015; 12: 185-199.